Current Trends in the Follow-up of Head and Neck Cancer Patients in the UK

被引:37
作者
Joshi, A.
Calman, F. [2 ]
O'Connell, M. [2 ]
Jeannon, J. -P.
Pracy, P. [3 ]
Simo, R. [1 ]
机构
[1] Guys Hosp, Dept Otorhinolaryngol Head & Neck Surg, Guys & St Thomas NHS Trust, London SE1 9RT, England
[2] Queen Elizabeth Univ Hosp, Birmingham, W Midlands, England
[3] Guys & St Thomas NHS Trust, Dept Clin Oncol, London, England
关键词
Follow-up; head and neck cancer; imaging; recurrence; surveillance; SQUAMOUS-CELL CARCINOMA; SURVEILLANCE; RECURRENCE; COSTS;
D O I
10.1016/j.clon.2009.11.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: The follow-up of patients with head and neck cancer is an essential aspect of their management. Follow-up provides support and reassurance for patients and will allow early detection of recurrence and second primary tumours. However, there is little evidence of a survival benefit from follow-up. With prolonged follow-up periods, multidisciplinary teams may be under increasing pressure to see more patients and this could have a negative effect on the time and quality of consultations given to individual patients. The aim of the present study was to analyse the current trends in the follow-up of head and neck cancer patients after treatment with curative intent in the UK. Materials and methods: A postal questionnaire was sent to all members of the British Association of Head and Neck Oncologists. Results: Three hundred and twenty-seven questionnaires were sent and 214 were returned, making a response rate of 65.4%. One hundred and ninety-eight (61%) of these were deemed appropriate for evaluation and of these 111 (56%) clinicians followed up patients for a minimum of 5 years with 25 (13%) following patients for 10 years and 44 (22%) for life. Within the set of clinicians following patients for 5 years, 24 (12%) followed up patients with salivary gland and thyroid malignancies for a longer period of time. All clinicians concurred that the reasons for follow-up are to support patients, to detect local recurrences or metastases, second primary tumours and to monitor and manage the complications of treatment. Conclusions: Most of the clinicians followed up their patients up to a minimum of 5 years, with a significant minority who followed up the patients treated for cancers of the head and neck for longer periods. More studies are needed to elucidate the rationale and evidence for follow-up and to determine the adequate period of surveillance. (C) 2009 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:114 / 118
页数:5
相关论文
共 19 条
[1]   THE VALUE OF FOLLOW-UP IN PATIENTS TREATED FOR SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK [J].
BOYSEN, M ;
LOVDAL, O ;
TAUSJO, J ;
WINTHER, F .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) :426-430
[2]   Detection of recurrent nasopharyngeal carcinoma: MR imaging versus CT [J].
Chong, VFH ;
Fan, YF .
RADIOLOGY, 1997, 202 (02) :463-470
[3]   Effective health care: management of head and neck cancers [J].
Collins, R ;
Flynn, A ;
Melville, A ;
Richardson, R ;
Eastwood, A .
QUALITY & SAFETY IN HEALTH CARE, 2005, 14 (02) :144-148
[4]   Follow-up for people with cancer: nurse-led services and telephone interventions [J].
Cox, K ;
Wilson, E .
JOURNAL OF ADVANCED NURSING, 2003, 43 (01) :51-61
[5]  
*DEP HLTH, 2000, REF GUID SUSP CANC
[6]   Survival in second primary malignancies of patients with head and neck cancer [J].
Di Martino, E ;
Sellhaus, B ;
Hausmann, R ;
Minkenberg, R ;
Lohmann, M ;
Westhofen, M .
JOURNAL OF LARYNGOLOGY AND OTOLOGY, 2002, 116 (10) :831-838
[7]   The dilemma of follow-up in head and neck cancer patients [J].
Haas, I ;
Hauser, U ;
Ganzer, U .
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2001, 258 (04) :177-183
[8]   Experience in qualitative and quantitative FDG PET in follow-up of patients with suspected recurrence from head and neck cancer [J].
Lapela, M ;
Eigtved, A ;
Jyrkkiö, S ;
Grénman, R ;
Kurki, T ;
Lindholm, P ;
Nuutinen, J ;
Sutinen, E ;
Solin, O ;
Bjornskov, I ;
Bretlau, P ;
Friberg, L ;
Holm, S ;
Jensen, M ;
Hansen, HS ;
Minn, H .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (07) :858-867
[9]  
LEEMANS CR, 1994, CANCER-AM CANCER SOC, V73, P187, DOI 10.1002/1097-0142(19940101)73:1<187::AID-CNCR2820730132>3.0.CO
[10]  
2-J